Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1) : Randomized, Double-Blind, Placebo-Controlled Phase 2 Dose-Finding Trial

This randomized, double-blind, placebo-controlled, dose-finding study assessed efficacy and safety of 1, 5, and 15 mg/h intravenous clazosentan, an endothelin receptor antagonist, in preventing vasospasm after aneurysmal subarachnoid hemorrhage. Patients (n=413) were randomized to placebo or clazose...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Stroke (1970) 2008-11, Vol.39 (11), p.3015-3021
Hauptverfasser:	LOCH MACDONALD, R, KASSELL, Neal F, MAYER, Stephan, RUEFENACHT, Daniel, SCHMIEDEK, Peter, WEIDAUER, Stephan, FREY, Aline, ROUX, Sebastien, PASQUALIN, Alberto
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Biological and medical sciences Dioxanes - adverse effects Dioxanes - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Female Glasgow Outcome Scale Humans Infarction - drug therapy Infarction - etiology Ischemia - drug therapy Ischemia - etiology Medical sciences Middle Aged Muscle Neurology Pharmacology. Drug treatments Placebos Pyridines - adverse effects Pyridines - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Subarachnoid Hemorrhage - complications Subarachnoid Hemorrhage - drug therapy Sulfonamides - adverse effects Sulfonamides - therapeutic use Tetrazoles - adverse effects Tetrazoles - therapeutic use Treatment Outcome Vascular diseases and vascular malformations of the nervous system Vasospasm, Intracranial - complications Vasospasm, Intracranial - drug therapy Vasospasm, Intracranial - mortality Vasospasm, Intracranial - prevention & control
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!